ONCY
Oncolytics Biotech Inc
$0.89
-0.03 (-3.26%)
At close · Jul 10
Market Cap
$105.90M
Shares
119,354,067
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$28.76M
-26.2%
FY2025
Diluted EPS
-$0.30
0%
FY2025
Operating Cash Flow
-$20.11M
-1.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 |
|---|---|---|
| $13.31M | $15.44M | |
| $15.41M | $10.1M | |
| $28.73M | $25.54M | |
| -$28.73M | -$25.54M | |
| $386K | $975K | |
| $45K | $2.84M | |
| -$28.68M | -$22.7M | |
| $79K | $95K | |
| -$28.76M | -$22.79M | |
| -$28.9M | -$23.32M | |
| USD/shares | -$0.30 | -$0.30 |
| USD/shares | -$0.30 | -$0.30 |
| shares | 95.86M | 76.48M |
| shares | 95.86M | 76.48M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Reportable Segment | -$28,725,000 | -$25,542,000 |